ClinicalTrials.gg
CompletedNCT05310032Updated Mar 20, 2024

A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses

A Phase 1 interventional study of HSG4112 and Placebo in Obesity, sponsored by Glaceum. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by Glaceum · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 137 studies in Obesity with a site in Korea, Republic of — 35 open to participants now, 46 under way, 27 of them phase 3. Obesity · Korea, Republic of.

Enrollment
99th of 117
36 · median 120
Started
2022
with 11 others
Phase 1
9 of 137
1 open now
Registered
77th of 137
by date
Lead sponsor
5 of 137
Glaceum

Among the 137 studies in Obesity with a site in Korea, Republic of, this one is the 99th largest by enrollment of the 117 interventional ones that give a count, is one of 12 that started in 2022, is one of 9 in phase 1, and was the 77th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

35 of the 137 studies in Obesity with a site in Korea, Republic of are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 19 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Obesity with a site in Korea, Republic of, or all of them as a file.
02

Study summary

  1. Study Objective

    i) To evaluate the safety, tolerability and pharmacokinetic/pharmacodynamic characteristics of HSG4112 after single and multiple oral administration of high doses in healthy subjects.

    ii) To evaluate the food effect on the pharmacokinetic characteristics of HSG4112 after a single oral administration of 1200 mg (6 tablets of HSG4112 200 mg) in healthy subjects.

  2. Background

    The previous phase 1 clinical trials investigating HSG4112 included dosage only up to 720 mg of HSG4112 in both healthy and obese subjects. Since obese patients have various comorbidities, unexpected drug interactions may occur due to concomitant drugs. Securing a 2- to 5-fold safety margin is needed to tolerate this issue. Therefore, this study is designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and food effects of high-dose HSG4112 in healthy subjects.

  3. Study Design and Plan

\<Part 1> This study is a randomized, open-label, single dosing, phase 1 clinical study. A unique randomization number will be assigned to each subject deemed eligible to participate in the study based on the inclusion/exclusion criteria. Each subject will be randomized to one of the two dose groups. 8 subjects will receive 800 mg of HSG4112 with a high-fat meal, and 12 subjects will be randomized to 2 different sequential groups. Each subject will receive a single dose of HSG4112 1200 mg via oral administration with a high-fat meal and in fasted condition, with a washout period of 21 days in between each dosing. When escalating the dose, the Investigator will review all of the available safety data from the preceding dose in a blinded manner to ensure if it is safe to escalate the dose. In order to evaluate safety and tolerability, assessments, such as vital signs, 12-lead ECG, laboratory test, pregnancy test, physical examination, and adverse event monitoring will be performed. Blood samples will be collected to evaluate the pharmacokinetic/pharmacodynamic characteristics of HSG4112.

\<Part 2> This study is a randomized, double-blind, placebo-controlled, multiple dosing, phase 1 clinical study. A unique randomization number will be assigned to each subject deemed eligible to participate in the study based on the inclusion/exclusion criteria. Each subject will be randomized to one of the two dose groups (800 mg or 1200 mg of HSG4112). In each dose group, 6 subjects will be randomized to receive 800 mg of HSG4112, and 2 subjects will be randomized to receive placebo, both with a high-fat meal. The subjects will be studied in a double-blind manner and will receive the investigational product (i.e., HSG4112 or placebo) via once-daily oral administration for 14 days. When escalating the dose, the Investigator will review all of the available safety data from the preceding dose in a blinded manner to ensure if it is safe to escalate the dose. In order to evaluate safety and tolerability, assessments, such as vital signs, 12-lead ECG, laboratory test, pregnancy test, physical examination, and adverse event monitoring will be performed. Blood samples will be collected to evaluate the pharmacokinetic/pharmacodynamic characteristics of HSG4112.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to comprehend and willing to sign an form approved by the IRB before screening.
  2. Adults between 19 and 50 years of age at screening.
  3. (BMI) between 18 and 24.9.

    • BMI (kg/m2) = Body weight (kg) / {Height (m)2}
  4. In good health, determined by no findings from medical history, physical examination, vital signs, 12-lead , and clinical laboratory test at screening, or subjects who are deemed acceptable by the Investigator regardless of the test results.
  5. For Part 2 (i.e., the multiple dose study), female subjects who have regular menstrual cycles(28±7 days) and who are not pregnant or lactating.

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any hepatic, kidney, neurological, immune, respiratory, endocrine, hematological, neoplastic, cardiovascular disease, or psychiatric disorder (e.g., mood disorder, obsessive-compulsive disorder).
  2. History of stomach or intestinal disorders (e.g., Chrons disease, ulcer) or surgeries - not including appendectomy, hemorrhoidectomy, or herniotomy - which may affect the pharmacokinetic or pharmacodynamic evaluation of the product.
  3. Significant history or clinical manifestation of to any drug compound (e.g., licorice-containing drugs, aspirin, antibiotics).
  4. One or more of the following laboratory test results at screening:

    • (SGPT) > 60 IU/L
    • Glucose (fasting) > 110 mg/dL or \< 70 mg/dL
  5. Systolic blood pressure of \< 90 mmHg or > 150 mmHg, or diastolic blood pressure of \< 60 mmHg or > 100 mmHg as determined by vital signs monitored after resting in sitting position for at least 3 minutes.
  6. History of drug/chemical abuse or tested positive in urine drug screen.
  7. Use or intend to use any prescription medications/products or phytotherapeutic/herbal/plant-derived preparations within 14 days prior to dosing, or any nonprescription medications/products (i.e., over-the-counter (OTC) drugs), health products, or vitamins within 7 days prior to dosing, unless deemed acceptable by the Investigator.
  8. Participation in any clinical study or bioequivalence study involving the administration of an investigational drug, including any study investigating HSG4112, within 6 months prior to dosing (i.e., within 6 months of the last dose from the previous study).
  9. Whole blood donation within 2 months prior to dosing, plasma/ donation within 1 month prior to dosing, or receipt of blood products within 1 month prior to dosing.
  10. Smoker. However, participation is acceptable if the subject has quit smoking at least 90 days prior to dosing.
  11. Alcohol consumption of > 21 units/week (1 unit = 10 g of pure alcohol) or unable to abstain from consuming alcohol during the study period, starting from 3 days prior to dosing.
  12. Ingestion of grapefruit-containing foods or beverages 24 hours prior to dosing until discharge, or unable to abstain from ingesting such foods or beverages during the same period.
  13. Unable to abstain from caffeine-containing foods or beverages (e.g., coffee, tea (e.g., black tea, green tea), soft drinks, coffee milk, energy drinks, sports drinks) during the admission period.
  14. Unable or unwilling to use acceptable methods for themselves or their spouse/partner during the entire study period and up to 28 days after the last dosing and subjects who satisfy at least one of the pregnancy-related criteria below:

    • females of who plan to use hormonal contraceptives or oral contraceptives during the study period
    • females of childbearing potential confirmed "positive" in a pregnancy test

      • "females of childbearing potential" refer to females who have experienced menarche and have not undergone a successful surgical sterilization procedure (i.e., hysterectomy, bilateral tubal ligation, bilateral salpingectomy, bilateral oophorectomy) or is not menopause (i.e., 12 months without menstruation).

        • Acceptable contraceptive methods include:

          1. Use of an intrauterine device, which has been proven highly effective.
          2. Physical contraception for subject or spouse/partner used with chemical sterilization (e.g., spermicide).
          3. Surgical sterilization (e.g., vasectomy, hysterectomy, tubal ligation, salpingectomy).
  15. Subjects who, in the opinion of the Investigator, should not participate in this study based on clinical laboratory test results or other reasons.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    HSG4112 800 mg Single Dose

    Single oral dosing of HSG4112 800 mg

    Drug: HSG4112

  • Experimental
    HSG4112 1200 mg Single Dose

    Single oral dosing of HSG4112 1200 mg with a high-fat meal or fasting condition, with a washout period of 21 days in between each dosing

    Drug: HSG4112

  • Experimental
    HSG4112 800 mg Multiple Dose

    Multiple oral dosing of HSG4112 1200 mg for 14 days

    Drug: HSG4112

  • Placebo comparator
    Placebo 800 mg Multiple Dose

    Multiple oral dosing of placebo 800 mg for 14 days

    Drug: Placebo

  • Experimental
    HSG4112 1200 mg Multiple Dose

    Multiple oral dosing of HSG4112 1200 mg for 14 days

    Drug: HSG4112

  • Placebo comparator
    Placebo 1200mg Multiple Dose

    Multiple oral dosing of placebo 1200 mg for 14 days

    Drug: Placebo

Interventions

  • Once-daily oral adminstration

    Also known as: 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol

  • DrugPlacebo

    Once-daily oral adminstration

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Assessment by Maximum Plasma Concentration of HSG4112

    Maximum Plasma Concentration of HSG4112 (Cmax)

    Time frame: Hour 0 to 192

  2. Pharmacokinetic Assessment by Maximum Plasma Concentration of HSG4112 at Steady State

    Maximum Plasma Concentration of HSG4112 at Steady State (Cmax,ss)

    Time frame: Hour 0 to 192

  3. Pharmacokinetic Assessment by Minimum Plasma Concentration of HSG4112 at Steady State

    Minimum Plasma Concentration of HSG4112 at Steady State (Cmin,ss)

    Time frame: Hour 0 to 192

  4. Pharmacokinetic Assessment by Average Plasma Concentration of HSG4112 at Steady State

    Average Plasma Concentration of HSG4112 at Steady State (Cavg,ss)

    Time frame: Hour 0 to 192

  5. Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity

    Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity (AUCinf)

    Time frame: Hour 0 to 192

  6. Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity at Steady State

    Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity at Steady State (AUCinf,ss)

    Time frame: Hour 0 to 192

  7. Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval

    Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval (AUCtau)

    Time frame: Hour 0 to 24

  8. Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval at Steady State

    Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval at Steady State (AUCtau,ss)

    Time frame: Hour 0 to 24

  9. Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point

    Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point (AUClast)

    Time frame: Hour 0 to 192

  10. Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point at Steady State

    Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point at Steady State (AUClast,ss)

    Time frame: Hour 0 to 192

  11. Pharmacokinetic Assessment by Half-Life of HSG4112

    Half-life of HSG4112 (T1/2)

    Time frame: Hour 0 to 192

  12. Pharmacokinetic Assessment by Half-Life of HSG4112 at Steady State

    Half-life of HSG4112 at Steady State (T1/2,ss)

    Time frame: Hour 0 to 192

  13. Pharmacokinetic Assessment by Time to Maximum Observed Plasma Concentration of HSG4112

    Time to Maximum Observed Plasma of HSG4112 (Tmax)

    Time frame: Hour 0 to 192

  14. Pharmacokinetic Assessment by Time to Maximum Observed Plasma Concentration of HSG4112 at Steady State

    Time to Maximum Observed Plasma Concentration of HSG4112 at Steady State (Tmax,ss)

    Time frame: Hour 0 to 192

  15. Pharmacokinetic Assessment by Oral Clearance of HSG4112

    Oral Clearance of HSG4112 (CL/F)

    Time frame: Hour 0 to 192

  16. Pharmacokinetic Assessment by Oral Clearance of HSG4112 at Steady State

    Oral Clearance of HSG4112 at Steady State (CLss/F)

    Time frame: Hour 0 to 192

  17. Pharmacokinetic Assessment by Volume of Distribution of HSG4112

    Volume of Distribution of HSG4112 (Vd/F)

    Time frame: Hour 0 to 192

  18. Pharmacokinetic Assessment by Volume of Distribution of HSG4112 at Steady State

    Volume of Distribution of HSG4112 at Steady State (Vdss/F)

    Time frame: Hour 0 to 192

  19. Safety and Tolerability Assessment by Adverse Event Monitoring

    Number of participants with observed advese events

    Time frame: Day 1 to 9 following the last administration

  20. Safety and Tolerability Assessment by Number of Participants with Change in Vital Signs

    Number of participants with clinically significant change in vital signs including blood pressure (mmHg) measured with blood pressure monitor, heart rate (beats per minute) measured with pulse oximeter, and body temperature (degrees Celcius) measured with thermometer

    Time frame: Day 1 to 9 following the last administration

  21. Safety and Tolerability Assessment by Number of Patients with Change in Physical Examination

    Number of participants with clinically significant change in physical examination

    Time frame: Day 1 to 9 following the last administration

  22. Safety and Tolerability Assessment by Number of Participants with Change in Laboratory Test

    Number of participants with clinically significant change in laboratory test assessed through hematology, blood biochemistry, urinalysis, and blood coagulation test

    Time frame: Day 1 to 9 following the last administration

  23. Safety and Tolerability Assessment by Number of Participants with Change in 12-Lead Electrocardiogram

    Number of participants with clinically significant change in 12-lead electrocardiogram

    Time frame: Day 1 to 9 following the last administration

Secondary outcomes

  1. Pharmacodynamic Assessment by Change in Body Weight [Part 2]

    Change in body weight

    Time frame: Days 1 to 17, Day 18, Day 20, Day 22 post-dose before first meal

  2. Pharmacodynamic Assessment by Change in Waist Circumference [Part 2]

    Change in waist circumference

    Time frame: Day 1, Day 8, Day 15, Day 22 post-dose before first meal

  3. Pharmacodynamic Assessment by Change in Body Fat Mass [Part 2]

    Change in body fat mass

    Time frame: Day 1, Day 8, Day 15, Day 22 post-dose before first meal

  4. Pharmacodynamic Assessment by Change in Body Fat Percentage [Part 2]

    Change in body fat percentage

    Time frame: Day 1, Day 8, Day 15, Day 22 post-dose before first meal

  5. Pharmacodynamic Assessment by Change of Biomarkers [Part 2]

    Measurement of biomarkers including leptin, adiponectin, insulin, C-peptide (connecting peptide), IL6 (interleukin 6), TNF-alpha (tumor necrosis factor alpha), and CCL2 (C-C motif ligand 2) from baseline to day of last dosing will be combined to assess the weight loss effect of HSG4112

    Time frame: Day 1 and 14 pre-dose

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Dec 2022, 7 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2022
First posted
Apr 4, 2022
StartActual
Apr 21, 2022
Primary completionActual
Dec 12, 2022
CompletionActual
Mar 31, 2023
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05310032
Lead sponsor
Glaceum
Responsible party
Sponsor
First posted
Apr 4, 2022
Start date
Apr 21, 2022
Primary completion
Dec 12, 2022
Completion
Mar 31, 2023
Last update
Mar 20, 2024

Study contacts

Kyung Sang Yu, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSG4112

Start the discussion